Jounce Therapeutics News

JNCEDelisted Stock  USD 1.88  0.00  0.00%   
About 56% of Jounce Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Jounce Therapeutics suggests that many traders are alarmed regarding Jounce Therapeutics' prospects. Jounce Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Jounce Therapeutics. The current market sentiment, together with Jounce Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Jounce Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Jounce Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Jounce daily returns and investor perception about the current price of Jounce Therapeutics as well as its diversification or hedging effects on your existing portfolios.
  
over six months ago at benzinga.com         
Board Member at Jounce Therapeutics Exercises Options Worth 236K
benzinga news
over six months ago at globenewswire.com         
Jounce Therapeutics Announces Closing of Tender Offer
Macroaxis News: globenewswire.com
over six months ago at benzinga.com         
Board Member at Jounce Therapeutics Exercises Options Worth 172K
benzinga news
over six months ago at benzinga.com         
Jounce Therapeutics Board Member Acquires 104,363 Shares After Exercising Company Stock Options
benzinga news
over six months ago at zacks.com         
United Therapeutics Q1 Earnings Beat, Sales Miss
zacks News
over six months ago at benzinga.com         
Director at Jounce Therapeutics Exercises Options Worth 111K
benzinga news
over six months ago at benzinga.com         
Board Member at Jounce Therapeutics Exercises Options Worth 324K
benzinga news
over six months ago at benzinga.com         
Jounce Therapeutics Board Member Acquires 74,950 Shares After Exercising Company Stock Options
benzinga news
over six months ago at finance.yahoo.com         
United Therapeutics Q1 Earnings Beat, Sales Miss
Yahoo News
over six months ago at benzinga.com         
Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options
benzinga news
over six months ago at benzinga.com         
Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options
benzinga news
over six months ago at news.google.com         
Jounce Therapeutics Announces Closing of Tender Offer - InvestorsObserver
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Jounce Therapeutics, Inc. Short Interest Down 11.4 percent in April
news
over a year ago at finance.yahoo.com         
The past five years for Jounce Therapeutics investors has not been profitable
Yahoo News
over a year ago at news.google.com         
5 Stocks to Buy as the Drug Industry Rebounds in 2023 - Yahoo Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Jounce Therapeutics that are available to investors today. That information is available publicly through Jounce media outlets and privately through word of mouth or via Jounce internal channels. However, regardless of the origin, that massive amount of Jounce data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jounce Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jounce Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jounce Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jounce Therapeutics alpha.

Jounce Therapeutics Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Stocks to Watch eBay, Etsy, Jounce Therapeutics, Dutch Bros, Cheesecake Factory
02/22/2023
2
Jounce Therapeutics Inc expected to post a loss of9cents a share - Earnings Preview
02/24/2023
3
Why Is Boxed Stock Down 41 percent Today
03/15/2023
4
JNCE STOCK ALERT Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders
03/27/2023
5
Jounce Up 21 percent on Accepting Concentras Buyout Offer
03/28/2023
6
Millennium Partners, L.P. UK Regulatory Announcement Form 8.3 ... - ACROFAN USA
03/30/2023
7
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
04/03/2023
8
Jounce Therapeutics, Inc. Short Interest Down 11.4 percent in April
05/01/2023
9
Jounce Therapeutics Announces Closing of Tender Offer
05/04/2023
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Other Consideration for investing in Jounce Stock

If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated